Transforming growth factor-β1 produced by ovarian cancer cell line HRA stimulates attachment and invasion through an up-regulation of plasminogen activator inhibitor type-1 in human peritoneal mesothelial cells

被引:57
作者
Hirashima, Y [1 ]
Kobayashi, H [1 ]
Suzuki, M [1 ]
Tanaka, Y [1 ]
Kanayama, N [1 ]
Terao, T [1 ]
机构
[1] Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Shizuoka 4313192, Japan
关键词
D O I
10.1074/jbc.M212187200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The processes of ovarian cancer dissemination are characterized by altered local proteolysis, cellular proliferation, cell attachment, and invasion, suggesting that the urokinase-type plasminogen activator (uPA) and its specific inhibitor ( plasminogen activator inhibitor type-1 (PAI-1)) could be involved in the pathogenesis of peritoneal dissemination. We showed previously that expression of uPA and PAI-1 in the human ovarian cancer cell line HRA can be down-regulated by exogenous bikunin (bik), a Kunitz-type protease inhibitor, via suppression of transforming growth factor-beta1 (TGF-beta1) up-regulation and that overexpression of the bik gene can specifically suppress the in vivo growth and peritoneal dissemination of HRA cells in an animal model. We hypothesize that the plasminogen activator system in mesothelial cells can be modulated by HRA cells. To test this hypothesis, we used complementary techniques in mesothelial cells to determine whether uPA and PAI-1 expression are altered by exposure to culture media conditioned by HRA cells. Here we show the following: 1) that expression of PAI-1, but not uPA, was markedly induced by culture media conditioned by wild-type HRA cells but not by bik transfected clones; 2) that by antibody neutralization the effect appeared to be mediated by HRA cell-derived TGF-beta1; 3) that exogenous TGF-beta1 specifically enhanced PAI-1 up-regulation at the mRNA and protein level in mesothelial cells in a time- and concentration-dependent manner, mainly through MAPK-dependent activation mechanism; and 4) that mesothelial cell-derived PAI-1 may promote tumor invasion possibly by enhancing cell-cell interaction. This represents a novel pathway by which tumor cells can regulate the plasminogen activator system-dependent cellular responses in mesothelial cells that may contribute to formation of peritoneal dissemination of ovarian cancer.
引用
收藏
页码:26793 / 26802
页数:10
相关论文
共 46 条
[1]   PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 - REACTIVE CENTER AND AMINO-TERMINAL HETEROGENEITY DETERMINED BY PROTEIN AND CDNA SEQUENCING [J].
ANDREASEN, PA ;
RICCIO, A ;
WELINDER, KG ;
DOUGLAS, R ;
SARTORIO, R ;
NIELSEN, LS ;
OPPENHEIMER, C ;
BLASI, F ;
DANO, K .
FEBS LETTERS, 1986, 209 (02) :213-218
[2]   A PRECISE, RAPID AND SENSITIVE IN-VITRO ASSAY TO MEASURE THE ADHESION OF OVARIAN TUMOR-CELLS TO PERITONEAL MESOTHELIAL CELLS [J].
CATTERALL, JB ;
GARDNER, MJ ;
JONES, LMH ;
THOMPSON, GA ;
TURNER, GA .
CANCER LETTERS, 1994, 87 (02) :199-203
[3]   The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent [J].
Devy, L ;
Blacher, S ;
Grignet-Debrus, C ;
Bajou, K ;
Masson, R ;
Gerard, RD ;
Gils, A ;
Carmeliet, G ;
Carmeliet, P ;
Declerck, PJ ;
Noël, A ;
Foidart, JM .
FASEB JOURNAL, 2002, 16 (02) :147-154
[4]  
Duffy MJ, 2002, CLIN CHEM, V48, P1194
[5]   INDUCTION OF C-FOS GENE-EXPRESSION BY UROKINASE-TYPE PLASMINOGEN-ACTIVATOR IN HUMAN OVARIAN-CANCER CELLS [J].
DUMLER, I ;
PETRI, T ;
SCHLEUNING, WD .
FEBS LETTERS, 1994, 343 (02) :103-106
[6]   Differential regulation of mesothelial cell fibrinolysis by transforming growth factor beta 1 [J].
Falk, P ;
Ma, C ;
Chegini, N ;
Holmdahl, L .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2000, 60 (06) :439-447
[7]   Metastatic dissemination of human ovarian epithelial carcinoma is promoted by α2β1-integrin-mediated interaction with type I collagen [J].
Fishman, DA ;
Kearns, A ;
Chilukuri, K ;
Bafetti, LM ;
O'Toole, EA ;
Georgacopoulos, J ;
Ravosa, MJ ;
Stack, MS .
INVASION & METASTASIS, 1998, 18 (01) :15-26
[8]  
Frey RS, 1997, CANCER RES, V57, P628
[9]   PHENOTYPIC DIFFERENCES IN CYTOKINE RESPONSIVENESS OF HYPERTROPHIC SCAR VERSUS NORMAL DERMAL FIBROBLASTS [J].
GARNER, WL ;
KARMIOL, S ;
RODRIGUEZ, JL ;
SMITH, DJ ;
PHAN, SH .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1993, 101 (06) :875-879
[10]   THE UROKINASE RECEPTOR IS REQUIRED FOR HUMAN MONOCYTE CHEMOTAXIS IN-VITRO [J].
GYETKO, MR ;
TODD, RF ;
WILKINSON, CC ;
SITRIN, RG .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (04) :1380-1387